서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 30 of 30

Issue DateTitle / Author(s) / CitationFileAltmetrics
2008-01
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer
DOI
2008-12
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
view fileDOI
2009-05
Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation

Lee, Jeong-Ok; Kim, Dae-Young; Lim, Joo Han; Seo, Myung-Deok; Yi, Hyeon Gyu; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Journal of Gastroenterology and Hepatology, Vol.24 No.5, pp.800-805

DOI
2010-02
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
DOI
2010-12
Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma
2012-01
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
DOI
2012-04
The Prognostic Significance of HER2 Positivity for Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen
2012-07
Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer
DOI
2013-01
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: A pooled analysis of 2 phase II trials

Kim, Sun Young; Shim, Eun Kyung; Yeo, Hyun Yang; Baek, Ji Yeon; Hong, Yong Sang; Kim, Dae Yong; Kim, Tae Won; Kim, Jee Hyun; Im, Seock-Ah; Jung, Kyung Hae; Chang, Hee Jin

International Journal of Radiation Oncology Biology Physics, Vol.85 No.1, pp.201-207

DOI
2013-03
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study

Chow, Louis W. C.; Tung, Stewart Y.; Ng, Ting-Ying; Im, Seock-Ah; Lee, Min-Hyuk; Yip, Adrian Y. S.; Toi, Masakazu; Glueck, Stefan

Expert Opinion on Investigational Drugs, Vol.22 No.3, pp.299-307

DOI
2016-03
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
DOI
2017-07
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
DOI
2017-10
Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer
DOI
2017-12
Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis
DOI
2018-03
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
DOI
2018-05
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
DOI
2019-02
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
DOI
2019-07
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
DOI
2019-08
A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
DOI
2019-09
GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer
DOI
2019-11
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
DOI
2020-02
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
DOI
2020-08
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
DOI
2021-03
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
DOI
2022-12
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Geyer, C.E.; Garber, J.E.; Gelber, R.D.; Yothers, G.; Taboada, M.; Ross, L.; Rastogi, P.; Cui, K.; Arahmani, A.; Aktan, G.; Armstrong, A.C.; Arnedos, M.; Balmana, J.; Bergh, J.; Bliss, J.; Delaloge, S.; Domchek, S.M.; Eisen, A.; Elsafy, F.; Fein, L.E.; Fielding, A.; Ford, J.M.; Friedman, S.; Gelmon, K.A.; Gianni, L.; Gnant, M.; Hollingsworth, S.J.; Im, S.-A.; Jager, A.; Johannsson, O.Th.; Lakhani, S.R.; Janni, W.; Linderholm, B.; Liu, T.-W.; Loman, N.; Korde, L.; Loibl, S.; Lucas, P.C.; Marme, F.; Martínez de Dueñas, Eduardo; McConnell, R.; Phillips, K.-A.; Piccart, M.; Rossi, G.; Schmutzler, R.; Senkus, Elżbieta; Shao, Z.; Sharma, P.; Singer, C.F.; Spanic, T.; Stickeler, E.; Toi, M.; Traina, T.A.; Viale, G.; Zoppoli, G.; Park, Y.H.; Yerushalmi, R.; Yang, H.; Pang, D.; Jung, K.H.; Mailliez, A.; Fan, Z.; Tennevet, Isabelle; Zhang, J.; Nagy, T.; Sonke, G.S.; Sun, Q.; Parton, M.; Colleoni, M.A.; Schmidt, M.; Brufsky, A.M.; Razaq, Wajeeha; Kaufman, B.; Cameron, D.; Campbell, C.; Tutt, A.N.J.; the OlympiA Clinical Trial Steering Committee and Investigators; Im, Seock-Ah

Annals of Oncology, Vol.33 No.12, pp.1250-1268

DOI
2023-04
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
DOI
2024
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
DOI
2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
DOI
2024-01
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
DOI
2024-02
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
DOI
1